



EI · CML

EUROPEAN INVESTIGATORS ON CML

**32<sup>nd</sup> MEETING**  
OF THE **EUROPEAN**  
**INVESTIGATORS ON**

# **CHRONIC MYELOID LEUKEMIA (EI-CML)**

**May 14–17, 2026**  
**Brno, Czech Republic**



## PROGRAM

---

### THURSDAY MAY 14, 2026

**Individual arrivals** to OREA Congress Hotel Brno (Hotel Voroněž),  
Křížkovského 47, Brno

**19:00** Buffet dinner at OREA Congress Hotel Brno

### FRIDAY MAY 15, 2026

**Individual breakfast** at OREA Congress Hotel Brno

**8:30** Departure to the meeting venue

**Meeting** at Augustinian Abbey, Mendlovo nám. 157/1, Staré Brno

**10:00–10:10** Jiří Mayer. Welcome and introduction

**10:10–18:34** Scientific program

---

#### CLINICAL TRIALS UPDATE I.

10:10–11:00

Session Chairs: Daniela Žáčková, Gianantonio Rosti

FAUSTO CASTAGNETTI

10:10–10:22

**Enrolment and study flow of the GIMEMA-GELMC phase II PEARL trial: asciminib as single agent or in combination with nilotinib in the 1st-line treatment of CML.**

ANDREAS HOCHHAUS

10:23–10:35

**Risk adapted asciminib based combination therapy in newly diagnosed patients.**

VALENTÍN GARCÍA-GUTIÉRREZ

10:36–10:48

**Update of PONTIAC study.**

(ponatinib in combination with asciminib clinical trial).

YULIA YAKOVLEVA

10:49–11:00

**Integrating asciminib into transplant protocols for chronic myeloid leukemia: strategy and practice.**

**11:00–11:20** Coffee break

---

## CLINICAL TRIALS UPDATE II.

11:20–13:00

**Session Chairs:** Dragana Milojkovic, Anna Lübking

JIŘÍ MAYER

11:20–11:32

**Cytogenetic findings in newly diagnosed CP CML patients: epidemiology and prognostic significance. An international study.**

VALENTÍN GARCÍA-GUTIÉRREZ

11:33–11:45

**Preliminary data from GELMC registry** (> 2000 pts from 45 centers).

GIUSEPPE SAGLIO

11:46–11:58

The title is to be finalized (prospective observational study).

CARLO GAMBACORTI-PASSERINI

11:59–12:11

**CML-OPERAP study.**

ANNAMARIA BRIOLI

12:12–12:24

**Update of blast crisis registry.**

FRANCK-EMMANUEL NICOLINI, DRAGANA MILOJKOVIC

12:25–12:37

**Sudden blast crisis.**

PHILIPPE ROUSSELOT

12:38–12:50

**Asciminib in R/R Ph+ ALL or LBC CML.**

YULIA YAKOVLEVA

12:51–13:00

**The outcome of patients with blast crisis chronic myeloid leukemia with and without allogeneic hemopoietic stem cell transplantation.**

**13:00–14:00** Buffet lunch at the Augustinian Abbey

---

## CLINICAL TRIALS UPDATE III & TFR I.

14:00–15:30

**Session Chairs:** Philippe Rousselot, Fabrizio Pane

ANNA TURKINA

14:00–14:12

**Vamotinib: results of Phase III study.**

HENRIK HJORTH-HANSEN

14:13–14:25

**BosuPeg 2-year data.**

TOMASZ SACHA

14:26–14:38

**A prospective study for patients resistant or intolerant to ponatinib.**

ELZA LOMAIA

14:39–14:51

**New generation tyrosine kinase inhibitors versus allogeneic stem cell transplantation in first chronic phase CML after failure of 2 or more TKIs.**

ANNA LÜBKING, STINA SÖDERLUND

14:52–15:04

**CML vaccination study.**

EKATERINA CHELYSHEVA

15:05–15:17

**CML and pregnancy: when a pregnancy is not safe? Cases with a high leukemic burden.**

DELPHINE REA

15:18–15:30

**TFR after non-optimal response to prior TKI.**

**15:30–15:50** Coffee break

---

## TFR II.

15:50–17:10

**Session Chairs:** Delphine Rea, Jeroen Janssen

FRANCOIS XAVIER MAHON

15:50–16:02

**TFR with the long follow up more than 10 wyeers.**

FABRIZIO PANE

16:03–16:18

**Final update on the SUSTRENIM study.**

DANIELA ŽÁČKOVÁ, JIŘÍ MAYER

16:19–16:31

**Brief final results of a stopping trial HALF: treatment cessation after a two-step TKI dose reduction.**

EKATERINA CHELYSHEVA

16:32–16:44

**READIT study and post-READIT observation: results of two-step TKI deescalation, TFR observation and post-TFR data of TKI restart in reduced doses.**

ANNA LÜBKING, STINA SÖDERLUND

16:45–16:57

**DASTOP2 – an update.**

CARMEN FAVA

16:58–17:10

**Nilotinib vs dasatinib for treatment-free remission in CML: a comparative study.**

**17:10–17:30** Coffee break

---

## CML BIOLOGY I.

17:30–18:34

**Session Chairs:** Thomas Lion, Tomasz Stoklosa

MHAIRI COPLAND

17:30–17:42

**Biomarkers of treatment-free remission in CML.**

NICK CROSS

17:43–17:55

**BCR::ABL1/GUSB halving times predict molecular response.**

KATEŘINA MACHOVÁ POLÁKOVÁ

17:56–18:08

**DNA-based MRD monitoring – implication in clinical practice (CML and Ph+ALL).**

SIMONA SOVERINI

18:09–18:21

**Clinical significance of ASXL1 mutations across different treatment modalities: where are we?**

KATEŘINA MACHOVÁ POLÁKOVÁ

18:22–18:34

**ASXL1 mutations association with high platelets count.**

**20:00** Dinner at OREA Congress Hotel Brno

---

## SATURDAY MAY 16, 2026

**Individual breakfast** at OREA Congress Hotel Brno

**8:30** Departure to the meeting venue

**Meeting** at Augustinian Abbey

**9:30–12:40** Scientific program

---

### PRESENTATIONS OF THE PHARMACEUTICAL COMPANIES

**Session Chairs:** Jane Apperley, Andreas Hochhaus

LEANNE HOLES, SENIOR DIRECTOR OF CLINICAL SCIENCE, TERNS PHARMA  
*20 MIN*

**CARDINAL: A phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML.**

DRAGANA MILOJKOVIC  
*20 MIN*

**Update on ELVN-001, a selective active site inhibitor of BCR::ABL1.**

---

### TFR III.

**Session Chairs:** Jane Apperley, Andreas Hochhaus

VALENTÍN GARCÍA-GUTIÉRREZ  
*10:15–10:27*

**Final results from RESTOP trial.**

JEROEN JANSSEN  
*10:28–10:40*

**Vaccinostop study for TFR prediction.**

**10:40–11:10** Coffee break

---

### CML BIOLOGY II & MISCELLANEOUS.

**Session Chairs:** Simona Soverini, Francois Xavier Mahon

HOMAS LION  
*11:10–11:22*

**Lessons learned from comprehensive sensitivity testing of single and compound BCR::ABL1 KD mutations.**

CARMEN FAVA  
*11:23–11:35*

**Targeting epigenetic and metabolic crosstalk in CML via butyrate induced HDAC inhibition.**

ELISABETTA ABRUZZESE  
*11:36–11:48*

**A third way of managing long term treatment in CML: the downgrading strategy.**

ANDREAS HOCHHAUS  
*11:49–12:01*

**Expectations and goals of patients. A German survey.**

MARKUS PFIRRMANN  
*12:02–12:14*

**Challenges in prognostic modelling using medical data.**

JANE APPERLEY  
*12:15–12:27*

**Opportunities of cooperation between EICML and CML specialized Working Group of EHA.**

RÜDIGER HEHLMANN  
*12:28–12:40*

**Closing remarks.**

**12:40–14:00** Buffet lunch at the Augustinian Abbey

**Interactive discussion**

**19:00** Dinner at Valoria restaurant, Bohunická 2, Brno

---

# SUNDAY MAY 17, 2026

**Individual breakfast** at OREA Congress Hotel Brno

**Individual departures**

**Transport:** the venue of the meeting is in the walking distance from the hotel (15 minutes, 1 km); however, shuttle will be provided too.

---

## NOTES

A large grid of red dots, intended for taking notes. The grid consists of approximately 20 columns and 30 rows of small red dots.

---

## SPONSORS AND SUPPORTERS OF THE MEETING

Platinum sponsor:



Golden sponsor:



Silver sponsor:



Bronze sponsor:



Other sponsors:

